@article{0c15b0b7f3ab46d2b50d2fff0556b691,
title = "The phase 3 pediatric anticoagulant era",
abstract = "In this issue of Blood, Brand{\~a}o et al report the findings of an open-label, single-arm, phase 3 trial of the direct oral thrombin inhibitor dabigatran for extended secondary thromboprophylaxis in children with a history of venous thromboembolism (VTE)",
author = "Goldenberg, {Neil A.} and Branchford, {Brian R.}",
note = "Funding Information: Conflict-of-interest disclosure: N.A.G. receives salary and research support from the National Institutes of Health and consultancy fees from Chiesi, Daiichi Sankyo Inc., Novartis, and the University of Colorado–affiliated Academic Research Organization CPC Clinical Research. B.R.B. declares no competing fi-nancial interests. n",
year = "2020",
month = feb,
day = "13",
doi = "10.1182/blood.2019004340",
language = "English (US)",
volume = "135",
pages = "459--460",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",
}